• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease.

作者信息

Jiang Z Gordon, Tapper Elliot B

机构信息

Division of Gastroenterology and Hepatology Beth Israel Deaconess Medical Center, Harvard Medical School Boston MA.

Division of Gastroenterology and Hepatology University of Michigan Ann Arbor MI.

出版信息

Hepatol Commun. 2019 Oct 1;3(10):1293-1295. doi: 10.1002/hep4.1386. eCollection 2019 Oct.

DOI:10.1002/hep4.1386
PMID:31592491
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6771157/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac1f/6771157/fd930b5d81e7/HEP4-3-1293-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac1f/6771157/fd930b5d81e7/HEP4-3-1293-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac1f/6771157/fd930b5d81e7/HEP4-3-1293-g001.jpg

相似文献

1
Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease.节省成本还是具有成本效益？非酒精性脂肪性肝病患者筛查中未解决的问题。
Hepatol Commun. 2019 Oct 1;3(10):1293-1295. doi: 10.1002/hep4.1386. eCollection 2019 Oct.
2
Cost-utility analysis of nonalcoholic steatohepatitis screening.非酒精性脂肪性肝炎筛查的成本效用分析
Eur Radiol. 2015 Nov;25(11):3282-94. doi: 10.1007/s00330-015-3731-2. Epub 2015 May 21.
3
Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.代谢综合征患者非酒精性脂肪性肝病超声筛查的成本效益分析
Medicine (Baltimore). 2017 Apr;96(17):e6585. doi: 10.1097/MD.0000000000006585.
4
Screening for nonalcoholic fatty liver disease-when, who and how?非酒精性脂肪性肝病筛查：何时、谁以及如何进行？
World J Gastroenterol. 2021 Sep 21;27(35):5803-5821. doi: 10.3748/wjg.v27.i35.5803.
5
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.使用非酒精性脂肪性肝病纤维化评分和振动控制瞬时弹性成像对非酒精性脂肪性肝病进行成本效益评估。
Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.
6
Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.瞬时弹性成像用于肝纤维化筛查：来自欧洲和亚洲六个前瞻性队列的成本效益分析。
J Hepatol. 2019 Dec;71(6):1141-1151. doi: 10.1016/j.jhep.2019.08.019. Epub 2019 Aug 27.
7
Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.2型糖尿病患者非酒精性脂肪性肝炎的筛查：一项成本效益分析
Dig Dis Sci. 2016 Jul;61(7):2108-17. doi: 10.1007/s10620-016-4044-2. Epub 2016 Jan 29.
8
Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease.运动即良药：运动训练对非酒精性脂肪性肝病的影响。
Curr Hepatol Rep. 2020 Dec;19(4):402-411. doi: 10.1007/s11901-020-00543-9. Epub 2020 Sep 9.
9
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.白藜芦醇治疗非酒精性脂肪性肝病的综合证据构建：临床前和临床荟萃分析
Front Pharmacol. 2023 Sep 12;14:1230783. doi: 10.3389/fphar.2023.1230783. eCollection 2023.
10
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的诊断、肝活检转诊及治疗建议
Mayo Clin Proc. 2015 Sep;90(9):1233-46. doi: 10.1016/j.mayocp.2015.06.013. Epub 2015 Jul 26.

引用本文的文献

1
Molecular dissection of the role of ACE2 in glucose homeostasis.血管紧张素转换酶2（ACE2）在葡萄糖稳态中作用的分子剖析
Physiol Rev. 2025 Jul 1;105(3):935-973. doi: 10.1152/physrev.00027.2024. Epub 2025 Feb 7.
2
Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?非酒精性脂肪性肝病与2型糖尿病：糖尿病专家的立场如何？
Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1. eCollection 2020.
3
Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population.

本文引用的文献

1
Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.实施“先FIB-4”策略对基层医疗转诊的非酒精性脂肪性肝病患者诊疗路径的影响
Hepatol Commun. 2019 Jul 29;3(10):1322-1333. doi: 10.1002/hep4.1411. eCollection 2019 Oct.
2
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.无创性纤维化模型诊断准确性：检测纤维化分期变化。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4.
3
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
在平均风险人群中，FIB-4 随后联合 M2BPGi 的序贯组合增强了对晚期肝纤维化的诊断性能。
J Clin Med. 2020 Apr 14;9(4):1119. doi: 10.3390/jcm9041119.
振动控制瞬时弹性成像评估非酒精性脂肪性肝病患者的纤维化和脂肪变性。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.
4
Use of Liver Imaging and Biopsy in Clinical Practice.肝脏成像与活检在临床实践中的应用。
N Engl J Med. 2017 Aug 24;377(8):756-768. doi: 10.1056/NEJMra1610570.
5
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
6
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.肝纤维化而非其他组织学特征与非酒精性脂肪性肝病患者的长期预后相关。
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
7
The natural history of nonalcoholic fatty liver disease: a population-based cohort study.非酒精性脂肪性肝病的自然史：一项基于人群的队列研究。
Gastroenterology. 2005 Jul;129(1):113-21. doi: 10.1053/j.gastro.2005.04.014.
8
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.美国城市人口中肝脂肪变性的患病率：种族的影响。
Hepatology. 2004 Dec;40(6):1387-95. doi: 10.1002/hep.20466.